Synchrotron radiation Fourier-transform infrared and Raman microspectroscopy study showing an increased frequency of creatine inclusions in the rat hippocampal formation following pilocarpine-induced seizures

J. Dulinska · Z. Setkowicz · K. Janeczko · C. Sandt · P. Dumas · L. Uram · K. Gzielo-Jurek · J. Chwiej

Received: 28 July 2011 / Revised: 15 September 2011 / Accepted: 9 October 2011 / Published online: 29 October 2011
© The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract In the present work, synchrotron radiation Fourier-transform infrared (SRFTIR) and Raman microspectroscopies were used to evaluate a possible role of creatine in the pathogenesis and progress of pilocarpine-evoked seizures and seizure-induced neurodegenerative changes in the rat hippocampal tissue. The main goal of this study was to identify creatine deposits within the examined brain area, to analyze their frequency in epileptic animals and naive controls and to examine correlations between the number of inclusions in the hippocampal formation of epileptic rats and the quantitative parameters describing animal behavior during 6-h observation period after pilocarpine injection. The presence of creatine in the brain tissue was confirmed based on the vibrational bands specific for this compound in the infrared and Raman spectra. These were the bands occurring at the wave-numbers around 2800, 1621, 1398, and 1304 cm⁻¹ in IR spectra and around 1056, 908 and 834 cm⁻¹ in the Raman spectra. Creatine was detected in eight of ten analyzed epileptic samples and in only one of six controls under the study. The number of deposits in epileptic animals varied from 1 to 100 and a relative majority of inclusions were detected in the area of the Dentate Gyrus and in the multiform hippocampal layer. Moreover, the number of creatine inclusions was positively correlated with the total time of seizure activity.

Keywords Pilocarpine-induced epilepsy · Creatine deposits · SRFTIR microspectroscopy and imaging · Raman microspectroscopy

Introduction

Epilepsy is one of the most frequently occurring neurological diseases. It is characterized by recurrent spontaneous seizures leading, without an appropriate therapeutic treatment, to severe cognitive and social impairments [1–4]. Changes underlying these impairments include seizure-induced variations in tissue levels of glutamate or GABA (gamma-aminobutyric acid), excessive activation of glutamate receptors, oxidative stress, overexpression of cytokines and finally apoptosis or necrosis of nerve cells [5, 6]. Despite the intensive investigations, the mechanisms underlying the mentioned abnormalities still remain poorly understood.

Animal models of epilepsy are valuable tools to study the pathogenesis of this disease and to evaluate potential antiepileptic drugs [7, 8]. Chronic models of acquired (symptomatic) epilepsy include those in which epilepsy-
like conditions are evoked by electrical (kindling model) or pharmacological stimuli (for example, pilocarpine and kainate models) in previously healthy animals, mostly rats [7]. In the most frequently used model of temporal lobe epilepsy, following the pilocarpine-induced seizures, numerous brain structures which are involved in the epileptiform activity may display different degrees of neurodegeneration, depending on the seizure intensity and duration. The neurodegenerative changes are particularly located in the sectors 1 and 3 of the Ammon’s horn (CA1 and CA3, respectively) [9] and among the processes suspected of leading to hippocampal anomalies, oxidative stress accompanying mitochondrial dysfunction is mainly taken into account [10].

In our previous studies, we analyzed the biochemical changes occurring in the CA3 sector and dentate gyrus (DG) of the rat hippocampal formation in the acute period after pilocarpine injection [11]. In animals suffering from seizures, we observed changes in the secondary structure of proteins (from α-helical to β-sheet) and the saturation level of phospholipids. The mentioned abnormalities were detected in the pyramidal cell layer of CA3 and in the multiform and molecular layers of DG area.

Carrying out the measurements using SRFTIR microspectroscopy, crystalline inclusions of unknown origin were noticed within hippocampal formation from epileptic animals. The preliminary analysis done during this experiment suggested that the mentioned deposits included creatine. Because similar creatine inclusions have been previously observed in the hippocampus of amyloid precursor protein transgenic mice as well as in the autopsy samples from people deceased with Alzheimer’s disease or amyotrophic lateral sclerosis [12–15], we decided to continue our study and verify the possible role of creatine in the pathogenesis and progress of pilocarpine-evoked seizures and seizure-induced neurodegenerative changes.

Brain, constituting only 2% of body mass, consumes almost 20% of total body energy requirements [16]. The most energy used in the nervous system is provided in the form of ATP by mitochondria [17]. Creatine, being a nitrogenous organic amino acid, plays important roles in this process. Creatine is an element of the brain creatine/phosphocreatine/creatine kinase (Cr/PCr/CK) system which serves as a temporal and spatial energy buffer [18]. However, the energy storage and a high-energy phosphate shuttle from mitochondria to the cytoplasmic places of consumption are not the only functions of creatine. It can also play a role in protein synthesis and in its phosphorylated form in membrane stabilization [19, 20]. Additionally, the studies of Almeida et al. showed that creatine had also to be considered as a neuromodulator or co-transmitter which was able to modify the activity of some postsynaptic receptors [21].

The key significance of creatine for the energetic metabolism and its other functions in the CNS have been evidenced by creatine deficiency syndromes resulting from inborn errors of creatine synthesis or transport. Patients suffering from them present clinical features including severe mental retardation, movement disorders, autism, and epilepsy [22, 23].

Troubles in CNS energy metabolism of different origin play critical roles in the progression of neurological diseases as a primary or secondary mechanism in neuronal death cascade. Therefore, the therapeutic potential of creatine for brain pathologies has recently been tested using animal models of neurodegenerative disorders, such as Parkinson’s disease, Huntington’s disease or amyotrophic lateral sclerosis [24–28]. In Parkinson’s disease, the treatment with creatine resulted in a significant protection against both CNS dopamine depletion and neuronal loss in the substantia nigra [24]. In an animal model of Huntington’s disease, creatine supplementation increased animals’ life span, decreased their brain atrophy and delayed the formation of mutant huntingtin aggregates [25]. For these two diseases also ongoing clinical trials seem to be very promising in contrast to amyotrophic lateral sclerosis for which subsequent clinical tests did not confirm efficacy of the treatment with the creatine [29–31].

In the present paper, two measurement techniques, i.e., SRFTIR and Raman microspectroscopy were used to examine the possible role of creatine in the process of epileptogenesis. Analysis of vibrational modes of molecules allowed us to detect creatine deposits within rat nervous tissue and to compare the frequencies of their occurrence in the postepileptic and control hippocampal formations. Additionally, correlations between the numbers of creatine inclusions and the animal seizure behavior parameters within the 6-h period after pilocarpine injection were calculated.

Materials and methods

Animals

All animal-use procedures were approved by the Bioethical Commission of the Jagiellonian University in accordance with international standards. Adult male Wistar rats were obtained from an animal colony of the Institute of Pediatrics, Collegium Medicum, Jagiellonian University, Krakow and maintained under conditions of controlled temperature (20±2 °C) and illumination (12-h light:12-h dark cycle). A solid diet (Labofeed) and water were available ad libitum.

Epilepsy induction and behavioral observations

The cholinergic agonist, pilocarpine, was used in order to induce seizures in rats. Pilocarpine was injected intra-
peritoneally (300 mg/kg, Sigma P6503) on the postnatal day 60. Scopolamine methyl bromide (1 mg/kg, Sigma S8502) was injected i.p. 30 min prior to pilocarpine to reduce its peripheral effects. After pilocarpine injection, the rats were continuously observed during the 6-h period. Motor symptoms were rated on the six-point scale used in our previous studies [32]. Additionally, the observations provided the data on general parameters of the status epilepticus such as: (1) the latency of the first motor sign, (2) the time when it occurred within the 6-h observation period, and (3) the time when the acute period ended. Ten epileptic animals were used in this study, four with intermediate and six with heavy seizures. The latency of the first motor signs varied from 10 to 20 min, while the duration of seizure activity within the observation period varied from 180 to 350 min.

Sample preparation

After 6-h observation of the animals' behavior, the rats were perfused with physiological saline solution of high analytical purity. The skulls were opened, and the brains were excised and deeply frozen in liquid nitrogen. Afterwards, they were cut with a cryomicrotome into 10-μm thick sections. The sections containing the dorsal part of the hippocampal formation were placed on MirrIR low-e microscopic slides and stored at −70 °C. The presence of creatine deposits was examined in the hippocampal tissue of ten epileptic and six control animals.

Data acquisition

The measurements of tissue samples were carried out in February 2010 at the SMIS beamline of SOLEIL synchrotron (Saint Aubin, France). SRFTIR microspectroscopy was the main analytical technique used in the investigation. The measurements were carried out in transfection mode using a Continuum XL infrared microscope equipped with a 50 μm MCT detector and coupled to an FTIR ThermoNicolet 5700 spectrometer. The beam size was reduced to 10×10 μm² using a double pass aperture to eliminate diffraction and a 32× NA 0.6 infinity corrected Schwarzschild objective. Infrared spectra were recorded between 650 and 4000 cm⁻¹ by co-adding 64 scans for each individual sample spectrum at a nominal physical resolution of 6 cm⁻¹. Spectra were collected and analyzed using the data acquisition software OMNIC (Version 8.0).

Raman microspectroscopy was used as an additional complementary measurement technique. The main goal of its application was to confirm the results obtained using SRFTIR microspectroscopy and to verify whether the observed creatine deposits were localized within the analyzed tissue and were not laboratory contaminants.

All Raman measurements were recorded using a DXR Raman microscope (ThermoNicolet) equipped with a 780 nm ThermoNicolet laser providing 14 mW of power on sample, edge filters, a charge coupled device detector and a 100×/0.9 numerical aperture objective giving a spot size of 0.9 μm at 780 nm. The spectra were recorded with one accumulation of 80 s from 50 to 3400 cm⁻¹. The microspectrometer was operated in non-confocal mode with a pinhole of 50 μm and a 400 lines/mm grating, giving a spectral resolution varying from 10.1 to 18.5 cm⁻¹. For depth profiles, vertical steps of 2 μm were performed through around 10 μm thick sample, and 2.5 μm steps were used for horizontal maps in the plan of the section.

The only pre-treatment performed on IR and Raman spectra was baseline correction. The mentioned procedure was used only in case of comparisons of the spectra from hippocampal inclusions, normal tissue and creatine (see Figs. 1 and 4). Chemical mapping of selected IR or Raman bands was done based on their areas after baseline subtraction. In this case, no preprocessing was performed on the spectral data.

Results

SRFTIR microspectroscopy study

The detailed microscopic observations of tissue slices including the hippocampal formation of epileptic animals showed the presence of quite a large number of inclusions of unknown origin. The preliminary measurements done in 2008 at SMIS beamline of SOLEIL suggested the presence of creatine in the mentioned deposits. Therefore, we decided to use two complementary measurement techniques, namely SRFTIR and Raman microspectroscopies in order to examine the possible role of creatine in the pathogenesis and progress of pilocarpine-induced epileptic seizures. For this purpose, the point IR maps were recorded for all the inclusions found within the area of the hippocampal formation in ten epileptic and six control samples.

![Fig. 1](https://example.com/fig1.jpg) The comparison of baseline corrected IR absorption spectra recorded for the analyzed hippocampal inclusion (B), pure creatine (C) and normal hippocampal tissue (A)
In Fig. 1, a typical spectrum of the analyzed hippocampal inclusion was compared with that from normal nervous tissue and with the spectrum of pure creatine. The presence of creatine in the examined inclusions was confirmed based on the IR absorption bands characteristic for this compound and occurring at the wavenumbers around 2800, 1621, 1398, and 1304 cm\(^{-1}\) [15]. Additionally, in order to exclude the presence of phosphocreatine within the deposits, for some of them two dimensional IR imaging was done and the obtained distributions of intensities of creatine bands were compared with chemical maps obtained for the absorption bands specific for the compounds containing phosphate group(s). In Fig. 2, the results of such chemical mapping carried out for inclusions from the selected CA3 epileptic area were presented. Similar maps recorded for epileptic DG area were presented in Electronic Supplementary Material Figure S1.

As one can notice from Fig. 2, a higher absorption of IR radiation at 1398 and 1304 cm\(^{-1}\) and lower at 1225 and 1080 cm\(^{-1}\) was correlated with the positions of inclusions what suggested that they contained creatine but not phosphocreatine.

From among six control samples only one contained creatine inclusions (25 inclusions mostly at multiform layer). In case of epileptic group, creatine aggregates were observed in eight of ten animals under investigation and the number of inclusions varied from 1 to 100.

In order to verify if the localization of creatine deposits is characteristic for specific cellular layers or regions of hippocampal formation the mean and median values of their number in the compared areas were calculated for epileptic group (eight epileptic animals in which creatine deposits were observed). The number of creatine inclusions in the pyramidal (pyr), granular (gran), multiform (mult), and molecular (mol) layers as well as in the areas of DG, hilus of DG, CA3, and CA1–CA2 were presented in Table 1 and Fig. 3.

As one can notice from Table 1 and Fig. 3, a relative majority of creatine inclusions was localized in the multiform layer and in the area of DG.

The further step of the investigation was to analyze correlations between the number of inclusions in the analyzed areas and the quantitative parameters describing the seizure behaviors induced by pilocarpine injection. The following behavioral parameters were taken into account: the latency of the first motor signs (T1), the maximal intensity of seizures (MAX) and the duration of the acute period (T). Spearman's rank correlation coefficients (\(r_s\)) were used as a measure of strength of the dependence between the number of creatine inclusions and the behavioral parameters. The values of Spearman’s rank correlation coefficients calculated for the examined cellular layers and areas of the hippocampal formation were presented in Table 2.

Table 1 The median and average values of the number of creatine inclusions in specific cellular layers and hippocampal regions in epileptic samples

| Cellular layer | Region | Total |
|----------------|--------|-------|
| pyr, gran, mult, mol | DG, H, CA3, CA1–CA2 |       |
| Median | Average | SD |
| pyr | 2 | 7 | 3 |
| gran | 1 | 7 | 3 |
| mult | 8 | 14 | 6 |
| mol | 7 | 9 | 3 |
| DG | 4 | 12 | 5 |
| H | 2 | 6 | 3 |
| CA3 | 0 | 6 | 3 |
| CA1–CA2 | 4 | 12 | 5 |
significant when its absolute value was ≥0.7 and the values fulfilling this condition were marked. The following correlations were observed between the number of creatine deposits and the parameters describing rat behavior in the acute period of status epilepticus:

- The quantity of creatine inclusions in granular ($r_s=0.76$, $p<0.05$) and molecular ($r_s=0.80$, $p<0.05$) layers was positively correlated with the total time of epileptic activity;
- Similar relation was observed for the DG ($r_s=0.85$, $p<0.05$) and for the whole hippocampal formation ($r_s=0.74$, $p<0.05$);
- The negative, statistically significant correlation, but with the absolute value of Spearman’s rank correlation coefficient less than 0.7, ($r_s=-0.61$, $p<0.05$) was found between the number of deposits in DG and the latency of the first motor signs.

In the next step of the analysis, the epileptic animals were divided into two groups: rats with intermediate (MAX=1.5 or 2) and heavy seizures (MAX=2.5 or 3). The first group included four whilst the second six animals. For both groups the medians of the number of creatine inclusions in specific cellular layers/areas were evaluated and the differences between them were tested using the U Mann–Whitney test. The mentioned statistical test did not confirm the existence of a significant difference in the number of deposits between the animals with intermediate and heavy seizures.

### Table 2
The values of Spearman’s rank correlation coefficients for the examined cellular layers and regions of the hippocampal formation

| Cellular layer | Region | Total |
|----------------|--------|-------|
|                | pyr    | gran  | mult | mol | DG | H | CA3 | CA1–CA2 |
| T1             | −0.20  | −0.51 | −0.04| −0.35| −0.61| −0.42| −0.04| 0.04 | −0.38 |
| MAX            | −0.18  | 0.38  | −0.08| −0.09| 0.26 | 0.07 | −0.40| −0.05| 0.07  |
| T              | 0.44   | **0.76**| 0.30 | **0.80**| **0.85**| 0.53 | 0.27 | 0.32 | **0.74**|

Raman microspectroscopy study

The results obtained using Raman spectroscopy evidently confirmed that the inclusions observed previously using SRFTIR microspectroscopy consisted of creatine. In Fig. 4, the Raman spectra recorded for normal nervous tissue, hippocampal inclusion and pure creatine were compared. The sharp shape of the bands present in the spectrum (B) may suggest the crystalline nature of the deposit.

In order to verify if creatine inclusions were present within the nervous tissue and were not laboratory contaminants on tissue surface, the line or 2D Raman depth profiles were recorded. As an example, one of them was presented in Fig. 5. Based on such measurements, we were able to confirm that creatine was located within the nervous tissue and the vertical size of the deposits varied between a few to around 20 μm.

Discussion and conclusions

The main goal of this study was to identify creatine deposits and to analyze their frequency in the hippocampal tissue in rats with pilocarpine-induced seizures and in naive controls. To achieve these goals, two complementary measurement techniques, allowing for analysis of vibrational modes of molecules, SRFTIR and Raman microspectroscopy, were used. The presence of creatine in the investigated inclusions was confirmed based on the
occurrence of the bands specific for the analyzed compound in the vibrational spectra. For IR absorption spectra, these were the bands occurring at the wavenumbers around 2800, 1621, 1398, and 1304 cm$^{-1}$. In turn, in Raman spectra the bands around 1056, 908, and 834 cm$^{-1}$ were mainly taken into account [12].

Our results showed that the frequency of creatine deposits was significantly higher in the animals with pilocarpine-induced seizures than in the control group. Creatine inclusions were detected in only one of six control animals while the presence of creatine was confirmed for 80% of epileptic animals. Thus, we can expect that the presence of creatine deposits may be an effect of pathological conditions occurring in the brain during the acute phase of status epilepticus.

During epileptic seizures there is an increased energy demand, and Cr/PCr/CK system may play a pivotal role in providing the energy necessary for seizure progression [33]. The presence of creatine deposits in epileptic animals may suggest a disturbed function of mitochondrial creatine kinase (CK) catalyzing creatine phosphorylation. Such a conclusion is very probable, taking into account the fact that reactive oxygen species can inactivate mitochondrial CK, by changing its octameric conformation into an inactivated dimeric form [21] and the data concerning an excessive free radical formation and lipid peroxidation.

![Fig. 4](image-url) The comparison of baseline corrected Raman spectra recorded for the analyzed hippocampal inclusion (B), pure creatine (C) and normal hippocampal tissue (A).

![Fig. 5](image-url) Raman microspectroscopy data showing hippocampal inclusions within the brain tissue. The spectral data were recorded in the vertical plane from +5 to −6 μm in depth from the surface of the tissue section along a 50 μm line. A Bright field image of two hippocampal inclusions; the red line overlays the axis of the depth slice. B Spectral image generated from the area of the C–H band containing signal from tissue and creatine. The surface of the tissue section appears clearly delineated at this wavelength (3–3.3 μm). C Spectral image generated from the area of the 850–815 cm$^{-1}$ band from creatine showing that the two inclusions are integrated within the nervous tissue. D Spectral image generated from the area of the amide I band from proteins. The surface of the section appears more fuzzy in this wavelength range (6–7 μm). E Spectra extracted from the map: normal tissue (blue), hippocampal inclusion (red) and glass beneath the tissue (green). The bands used to generate the spectral images are marked by stars.
observed in different brain areas during status epilepticus induced by pilocarpine and in the lithium–pilocarpine model [34–38]. In agreement with such thesis are also our previous results showing an increased lipid saturation (a marker of excessive oxidative stress) and conformational changes of proteins in the DG and CA3 hippocampal areas from animals treated with pilocarpine [11].

On the other hand, the study of Almeida et al. [21] showed that creatine was released from central neurons in a manner typical of classical neurotransmitters—upon depolarization of brain tissue depending on the level of extracellular Ca²⁺ ions and involving activation of voltage-dependent Na⁺ and K⁺ channels. The level of electrically evoked creatine release was diminished in the absence of extracellular Ca²⁺. On the other hand, the blockade of action-potential with an Na⁺ channel inhibitor reduced, whereas the blockade of K⁺ channels enhanced its electrically stimulated release [21]. Taking into account the results of Almeida et al. and the conditions occurring in the nerve cells during excessive discharges, we conclude that the increased frequency of creatine inclusions may also be connected with its neuromodulatory role.

For many years, cerebral creatine was believed to be principally of peripheral origin [39], but the works of Braissant et al. showed that glycineamidinotransferase and guanidoacetate methyltransferase, two enzymes necessary for creatine synthesis and function, were also expressed in the brain and, therefore, the brain was shown to be capable of its own creatine synthesis [40, 41]. However, in spite of brain synthesis of creatine, according to Tachikawa et al. [42], the brain barriers might be key determinants of the levels of guanidine compounds, including creatine, in the brain and cerebrospinal fluid. Since, changes in the blood–brain barrier permeability may be a common outcome of single and repeated seizures, the other possible explanation for the increased presence of creatine deposits in the epileptic brain may be seizure-induced blood–brain barrier damage resulting in its increased permeability for peripheral creatine [43].

Conclusions

In the present work, SRFTIR and Raman microspectroscopy were used to confirm the presence of creatine in inclusions localized within the hippocampal tissue from rats with pilocarpine-induced seizures. The comparison of epileptic and control rats showed for the first time an increased frequency of creatine inclusions in the epileptic animals. Additionally, the number of inclusions detected in the epileptic animals was positively correlated with the total time of seizure activity within the 6-h observation period. The obtained results may suggest seizure-induced disrup-

References

1. Chang BS, Lowenstein DH (2003) N Engl J Med 349:1257–1266
2. Karanassios V (2004) Spectroc Acta Pt B-Atom Spectr 59:909–928
3. Karanassios V, Johnson K, Smith AT (2007) Anal Bioanal Chem 388:1595–1604
4. Engel J, Pedley TA (2008) Epilepsia: a comprehensive textbook. Lippincott, Williams &Wilkins, Philadelphia
5. Haut SR, Veliskova J, Moshe SL (2004) Lancet Neurol 3:608–617
6. Fujikawa DG (2005) Epilepsy Behav 7:3–11
7. Loscher W (2002) Epilepsia Res 50:105–123
8. Sharma AK, Reams RY, Jordan WH, Miller MA, Thacker HL, Snyder PW (2007) Toxicol Pathol 35:984–999
9. Wasterlain CG, Fujikawa DG, Penix L, Sankar R (1993) Epilepsia 34:37–53
10. Patel M (2004) Free Radic Biol Med 37:1951–1962
11. Chwiej J, Dulinska J, Janeczko K, Dumas P, Eichert D, Dudala J, Setkowicz Z (2010) J Chem Neuroanat 40:140–147
12. Gallant M, Rak M, Szeghalmi A, Del Bigio MR, Westaway D, Yang J, Julian R, Gough KM (2006) J Biol Chem 281:5–8
13. Burklén TS, Schlattner U, Homayouni R, Gough K, Rak M, Szeghalmi A, Wallimann T (2006) J Biomed Biotech 2006:1
14. Kastylak MZ, Szczerskowska-Boruchowska M, Adamek D, Tomik B, Lankosz M, Gough KM (2010) Neuroscience 166:1119–1128
15. Szczerskowska-Boruchowska M, Chwiej J, Dumas P, Tomik B, Adamek D, Lankosz M (2010) Spectrosc Eur 22:17–20
16. Shulman RG, Rothman DL, Behar KL (2004) Hyder F 27:489–495
17. Wong-Riley MT (1989) Trends Neurosci 12:94–101
18. Bessman SP, Carpenter CL (1985) Ann Rev Biochem 54:831–862
19. Sipila I, Rapola J, Simell O, Vannas A (1981) N Engl J Med 304:867–870
20. Sharov VG, Saks VA, Kupriyanov VV, Lakomkin VL, Kapelko VL, Steinschneider AYa, Javadov SA (1987) J Thorac Cardiovasc Surg 94:749–761
21. Almeida LS, Salomons GS, Hogenboom F, Jakobs C, Schoffelmeier AN (2006) Synapse 60:118–123
22. Béard E, Braissant O (2010) J Neurochem 115:297–313
23. Nasrallah F, Feki M, Kaabachi N (2010) Pediatr Neurol 42:163–171
24. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF (1999) Exp Neurol 157:142–149
25. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuehmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF (2000) J Neurosci 20:4389–4397
26. Ellis AC, Rosenfeld J (2004) CNS Drugs 18:967–980
27. Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF (2004) J Neurochem 88:576–582
28. Zhang W, Narayanan M, Friedlander RM (2003) Ann Neurol 53:267–270
29. Adhihetty PJ, Beal MF (2008) Neuromol Med 10:275–290
30. Shefler JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, Urbinelli L, Qureshi M, Zhang H, Pestrone A, Caress J, Donofrio P, Sorenson E, Bradley W, Lomen-Hoerth C, Pioro E, Rezania K, Ross M, Pascuzzi R, Heiman-Patterson T, Tandan R, Mitumoto H, Rothstein J, Smith-Palmer T, MacDonald D, Burke D (2004) Neurology 63:1656–1661
31. Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, Phillips LH, Chapin J, Gelinas DF, Lou JS (2008) Amyotroph Lateral Scler 9:266–272
32. Setkowicz Z, Ciarch M, Gzik R, Janeczko K (2004) Epilepsy Res 61:63–72
33. Kim DW, Yeo SI, Ryu HJ, Kim JI, Song HK, Kwon OS, Choi SY, Kang TC (2010) BMC Neurosci 11:141
34. Freitas RM, Souza FCF, Vasconcelos SMM, Viana GS, Fonteles MMF (2005) FEBS J 272:1307–1312
35. Freitas RM (2009) Neurosci Lett 462:225–229
36. Tejada S, Roca C, Sureda A, Rial RV, Gamundi A, Esteban S (2006) Brain Res Bull 69:587–592
37. Tejada S, Sureda A, Roca C, Gamundi A, Esteban S (2007) Brain Res Bull 71:372–375
38. Peternel S, Pilipović K, Župan G (2009) Prog Neuropsychopharmacol Biol Psychiat 33:456–462
39. Wyss M, Kaddurah-Daouk R (2000) Physiol Rev 80:1107–1213
40. Braissant O, Henry H, Loup M, Eilers B, Bachmann C (2001) Mol Brain Res 86:193–201
41. Braissant O, Henry H, Villard AM, Speer O, Wallimann T, Bachmann C (2005) BMC Dev Biol 5:9
42. Tachikawa M (2011) Hosoya K 8:13
43. Sahin D, Ilbay G, Ates N (2003) Pharmacol Res 48:69–73